Intermediate Dose Cytarabine and Idarubicin for Salvage Therapy of Acute Myeloid Leukemia

摘要: Between September 1991 and May 1996, 56 patients with refractory or relapsed acute myeloid leukemia (AML) were treated one cycle of timed sequential chemotherapy (TSC) consisting intermediate-dose (ID) ara-C (1.0 g/m2 every 12 h) on days 1, 2, 8, 9, idarubicin (IDA, 10 mg/m2) 3, 4, 10, 11. The study population included 22 AML, 33 late first relapse occurring after a complete remission ≥ 6 months, 1 patient for whom the clinical course before salvage therapy was unknown. Of entered onto study, 25 (45%) achieved (CR), 8 (14%) partial (PR), 11 (20%) classified as treatment failure due to resistant disease, (21%) died within 42 initiation therapy, mainly infections. Response strongly influenced by disease status 55% achieving CR compared 32% refractoryAML. Severe myelosuppression observed in most resulting fever documented infections 70–90% them whereas nonhematologic toxicity tolerable. Among who CR, received no postremission 2 cycles IDA (8 etoposide (150 3 consolidation, underwent an allogeneic autologous bone marrow transplantation (BMT), lost follow-up. Overall, median follow-up 44 duration is 9 survival months well. We conclude that this regimen has significant antileukemic efficacy, especially AML durable (≥ months). short not eligible BMT, however, emphasizes need optimizing early postinduction therapy.